Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating mFOLFOX/mFOLFIRI vs mFOLFOX in Advanced Biliary Tract Cancer
NCT07062536Phase 2Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Aug 2025
- Primary completion
- Apr 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in biliary tract cancer (BTC) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Overall Survival Rate at 6 months. Started Aug 2025; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07062536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062536.